Government Support Helps Viromed Advance New Medical Technology

Backed by strong public investment, Viromed accelerates innovative, drug-free solutions for respiratory care and wound healing.

In a major boost to the future of medical technology, Germany-based Viromed Medical has secured substantial financial support from the German Federal Ministry of Research to advance its cutting-edge cold plasma platform.

As reported in an industry update highlighted by CIO Bulletin, the funding, amounting to a high six-figure euro grant will power the development of two key systems: PulmoPlas® and ViroCap®. These technologies are designed to tackle critical healthcare challenges without relying on traditional drugs.

PulmoPlas® focuses on eliminating harmful pathogens in the lungs of critically ill patients on ventilators, while ViroCap® offers a contact-free solution for faster and safer wound healing in dermatology. Both innovations represent a shift toward non-pharmacological treatments, a growing area of interest in modern medicine.

This funding is a strong validation for Viromed’s technology and its potential to transform patient care. Beyond funding, Viromed is also strengthening its production capabilities by planning to acquire relyon plasma GmbH, aiming to streamline its entire value chain.

While investors watch ongoing clinical trials closely, the real story lies in the technology itself. With regulatory approvals on the horizon, Viromed’s innovations could soon redefine how hospitals treat infections and wounds, marking a significant leap forward in medical technology, as CIO Bulletin observes.